Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia.

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
• Histone methylation plays a crucial role in cancer development and progression.
• Identifying novel molecular subtypes is essential for personalized treatment strategies in AML.

Purpose of the Study:

• To identify novel molecular subtypes of AML based on histone methylation modification regulators (HMMRs).
• To establish a scoring system (M-RiskScore) for predicting AML treatment response and prognosis.
• To validate the clinical utility of the identified subtypes and scoring system.

Main Methods:

• Utilized gene expression and clinical data from TCGA and GEO databases for AML patients.
• Performed consensus clustering based on 24 HMMRs to define molecular subtypes.
• Developed the M-RiskScore using differential expression, Cox, and lasso regression analyses.
• Validated the findings using an independent GSE dataset.

Main Results:

• Identified two distinct AML subtypes with significant differences in HMMRs expression, clinical features, and survival.
• Established the M-RiskScore, demonstrating its ability to predict patient survival and response to decitabine and IA regimen therapies.
• Low M-RiskScore correlated with better survival and decitabine response; high M-RiskScore indicated decitabine resistance but benefit from IA therapy.

Conclusions:

• HMMRs expression serves as a potential strategy for AML subtyping.
• Targeting histone methylation may be beneficial for specific AML subtypes (AML-M0, NPM1-mutant).
• M-RiskScore is a valuable prognostic biomarker and a guide for selecting chemotherapy regimens in AML.